Role of microRNA-375 in efficacy evaluation and prediction of laparoscopic gastric bypass in treating type 2 diabetes mellitus

doi:10.3877/cma.j.issn.2095-9605.2016.04.007

Abstract

Abstract:

Objective

To investigate the role of microRNA-375 (miR-375) in efficacy evaluation and prediction of laparoscopic Roux-en-Y gastric bypass (LRYGB) in treating type 2 diabetes mellitus (T2DM).

Methods

Clinical and laboratory data of 17 patients with T2DM undergoing LRYGB in the First Affiliated Hospital of Soochow University from May 2010 to March 2013 were retrospectively studied. Among the 17 patients, 7 were males and 10 were females with an average age of (46±13) years old. The informed consents of all patients were obtained and the local ethical committee approval had been received. Body mass index (BMI), fasting plasma glucose (FPG), glycosylated hemoglobin A1c (HbA1c), homeostatic model assessment of insulin resistance (HOMA-IR), fasting insulin (FIns), fasting C peptide (FCP), total cholesterol (TC), triglyceride (TG), high density lipoprotein cholesterol (HDL-C), low density lipoprotein cholesterol (LDL-C) and miR-375 of all the patients were collected and compared before and 1, 3, 6 months after surgery. The comparisons of clinical and laboratory data before and after surgery were conducted using t test and Mann-Whitney U test, and the correlation analysis between miR-375 and each factor was conducted using Spearman rank correlation analysis.

Results

All patients received LRYGB successfully. At 6 months after LRYGB, BMI was (26±5) kg/m², FPG was (6.3±1.7) mmol/L, HbA1c was (6.5±0.8)%, FIns was 6.1[3.5, 8.6] mU/L, HOMA-IR was 1.9[1.0, 2.6], TC was (4.1±1.1) mmol/L, TG was (0.9±0.4) mmol/L, LDL-C was (2.3±0.7) mmol/L and miR-375 was 0.06[0.00, 0.12], which were significantly lower than (33±7) kg/m², (11.1±3.6) mmol/L, (9.3±1.6)%, 12.7[3.6, 19.3] mU/L, 5.4[1.9, 13.7], (5.0±1.0) mmol/L, (3.6±4.0) mmol/L, (3.1±0.7) mmol/L and 1.20[0.60, 1.85] before operation respectively (P<0.05); and HDL-C of these patients was (1.23±0.19) mmol/L, which was significantly higher than (1.05±0.14) mmol/L before operation. The correlation analysis showed that miR-375 was positively correlated with BMI, TC, TG, LDL-C, HbA1c, FPG, FIns, FCP and HOMA-IR respectively (P<0.05).

Conclusions

MiR-375 is closely related to blood glucose control and improvement of lipid and insulin resistance. Owing to the convenience and feasibility of being tested in serum, miR-375 may become a new biomarker, which can be used to evaluate and predict the curative effect of LRYGB on T2DM.

Key words: MicroRNA-375, Laparoscopic Roux-en-Y gastric bypass, Diabetes mellitus, type 2

Jun Yin, Zheng Zhu, Feng Guo, Zhongqi Mao. Role of microRNA-375 in efficacy evaluation and prediction of laparoscopic gastric bypass in treating type 2 diabetes mellitus[J]. Chinese Journal of Obesity and Metabolic Diseases(Electronic Edition), 2016, 02(04): 213-218.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhfpydxbdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-9605.2016.04.007

https://zhfpydxbdzzz.cma-cmc.com.cn/EN/Y2016/V02/I04/213

Figures/Tables 2

References 13

[1]	Jacobsen A, Silber J, Harinath G, et al. Analysis of microRNA-target interactions across diverse cancer types[J]. Nat Struct Mol Biol, 2013, 20(11):1325-1332.
[2]	Goodwin AJ, Guo C, Cook JA, et al. Plasma levels of microRNA are altered with the development of shock in human sepsis: an observational study[J]. Crit Care, 2015, 18(19):440.
[3]	Navickas R, Gal D, Laucevičius A, et al. Identifying circulating microRNAs as biomarkers of cardiovascular disease: a systematic review[J]. Cardiovasc Res, 2016, 111(4):322-337.
[4]	van de Bunt M, Gaulton KJ, Parts L, et al. The miRNA profile of human pancreatic islets and beta-cells and relationship to type 2 diabetes pathogenesis[J]. PLoS One, 2013, 8(1):e55272.
[5]	Zhu H, Leung SW. Identification of microRNA biomarkers in type 2 diabetes: a meta-analysis of controlled profiling studies[J]. Diabetologia, 2015, 58(5):900-911.
[6]	International Diabetes Federation. IDF Diabetes Atlas. 7th ed[R]. Brussels:IDF, 2015. URL
[7]	Buchwald H, Estok R, Fahrbach K, et al. Weight and 2 diabetes after bariatric surgery: systematic review and meta-analysis[J]. Am J Med, 2009, 122(3):248-256.
[8]	Chen X, Ba Y, Ma L, et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases [J]. Cell Res, 2008, 18(10):997-1006．
[9]	Gilad S, Meiri E, Yogev Y, et al. Serum microRNAs are promising novel biomarkers[J]. PLoS One, 2008, 3(9):e3148．
[10]	Laterza OF, Lim L, Garrett-Engele PW, et al. Plasma MicroRNAs as sensitive and specific biomarkers of tissue injury[J]. Clin Chem, 2009, 55(11):1977-1983．
[11]	Poy MN, Eliasson L, Krutzfeldt J, et al. A pancreatic islet-specific microRNA regulates insulin secretion[J]. Nature, 2004, 432(7014):226-230.
[12]	Erener S, Mojibian M, Fox JK, et al. Circulating miR-375 as a biomarker of β-cell death and diabetes in mice[J]. Endocrinology, 2013, 154(2):603-608.
[13]	Kim WH, Lee JW, Suh YH, et al. Exposure to chronic high glucose induces beta-cell apoptosis through decreased interaction of glucokinase with mitochondria: downregulation of glucokinase in pancreatic beta-cells. Diabetes[J], 2005, 54(9):2602-2611.

观察时间	BMI （kg/m²，±s）	体重（kg，±s）	腰围（cm，±s）	TC （mmol/L，±s）	TG （mmol/L，±s）	HDL-C （mmol/L，±s）	LDL-C （mmol/L，±s）
术前	33±7	92±29	106±15	5.0±1.0	3.6±4.0	1.05±0.14	3.1±0.7
术后1个月	30±6^a	84±25^a	99±16^a	4.1±1.1^a	1.5±1.0^a	1.04±0.16	2.6±0.8^a
术后3个月	28±5	76±20	94±14	4.2±1.1	1.4±1.3	1.10±0.16	2.4±0.7
术后6个月	26±5	71±18	88±13	4.1±1.1	0.9±0.4	1.23±0.19^a	2.3±0.7
统计值	t=8.241	t=6.446	t=8.648	t=3.956	t=2.863	t=–5.128	t=2.431
P值	<0.05	<0.05	<0.05	<0.05	<0.05	<0.05	<0.05
观察时间	FPG （mmol/L，±s）	HbA1c （%，±s）	FIns （mU/L，M[P25，P75]）	FCP （μg/L，M[P25，P75]）	HOMA-IR （M[P25，P75]）	miR-375 （M[P25，P75]）
术前	11.1±3.6	9.3±1.6	12.7[3.6，19.3]	1.9[1.3，3.1]	5.4[1.9，13.7]	1.20[0.60，1.85]
术后1个月	6.8±1.7^a	7.4±1.2^a	6.1[3.8，7.6]^a	1.8[1.3，2.3]	2.0[1.1，2.3]^a	0.33[0.16，0.52]^a
术后3个月	6.6±0.8	6.8±0.8	6.4[3.4，8.1]	1.6[1.4，2.1]	1.7[1.0，2.6]	0.22[0.06，0.29]
术后6个月	6.3±1.7	6.5±0.8	6.1[3.5，8.6]	1.7[1.3，2.2]	1.9[1.0，2.6]	0.06[0.00，0.12]
统计值	t=5.066	t=6.834	Z=–1.597	Z=–0.892	Z=–2.428	Z=–4.899
P值	<0.05	<0.05	<0.05	>0.05	<0.05	<0.05

观察时间	BMI （kg/m²，±s）	体重（kg，±s）	腰围（cm，±s）	TC （mmol/L，±s）	TG （mmol/L，±s）	HDL-C （mmol/L，±s）	LDL-C （mmol/L，±s）
术前	33±7	92±29	106±15	5.0±1.0	3.6±4.0	1.05±0.14	3.1±0.7
术后1个月	30±6^a	84±25^a	99±16^a	4.1±1.1^a	1.5±1.0^a	1.04±0.16	2.6±0.8^a
术后3个月	28±5	76±20	94±14	4.2±1.1	1.4±1.3	1.10±0.16	2.4±0.7
术后6个月	26±5	71±18	88±13	4.1±1.1	0.9±0.4	1.23±0.19^a	2.3±0.7
统计值	t=8.241	t=6.446	t=8.648	t=3.956	t=2.863	t=–5.128	t=2.431
P值	<0.05	<0.05	<0.05	<0.05	<0.05	<0.05	<0.05
观察时间	FPG （mmol/L，±s）	HbA1c （%，±s）	FIns （mU/L，M[P25，P75]）	FCP （μg/L，M[P25，P75]）	HOMA-IR （M[P25，P75]）	miR-375 （M[P25，P75]）
术前	11.1±3.6	9.3±1.6	12.7[3.6，19.3]	1.9[1.3，3.1]	5.4[1.9，13.7]	1.20[0.60，1.85]
术后1个月	6.8±1.7^a	7.4±1.2^a	6.1[3.8，7.6]^a	1.8[1.3，2.3]	2.0[1.1，2.3]^a	0.33[0.16，0.52]^a
术后3个月	6.6±0.8	6.8±0.8	6.4[3.4，8.1]	1.6[1.4，2.1]	1.7[1.0，2.6]	0.22[0.06，0.29]
术后6个月	6.3±1.7	6.5±0.8	6.1[3.5，8.6]	1.7[1.3，2.2]	1.9[1.0，2.6]	0.06[0.00，0.12]
统计值	t=5.066	t=6.834	Z=–1.597	Z=–0.892	Z=–2.428	Z=–4.899
P值	<0.05	<0.05	<0.05	>0.05	<0.05	<0.05

Please choose a citation manager

Content to export